Biosimilars Market by Drug Clinical Trail Status of Key Companies Amgen, Sandoz, Pfizer, Biocon, Teva Pahrmaceutical, Celltrion Analysis Report 2020 to 2025

Biosimilars are highly similar, comparable version of biologics, which undergo clinical trials to demonstrate that they have comparable safety, quality and efficacy to an approved biologic medicine. When the patent of the original product expires, biosimilars can be manufactured which are approved officially. Moreover, biologics are more complex than biosimilars drugs, both in composition and method of manufacture. Biosimilars will not be exact replicas of an approved biologic medicine but may instead show high similarity. Furthermore, in the United States, approximately 45%, i.e. 133 million of people have suffered with at-least one chronic disease. According to National Cancer Institute of America, in 2017 the national expenditures for cancer care was USD 147.3 billion. Whereas, in 2018, 3.9 million new cases of cancer and over 1.9 million cancer deaths were estimated in Europe. Hence, the high prevalence of chronic diseases such as cancer, growth hormone deficiency and anemia is projected to fuel the demand of biosimilars in near future.

To Get Overview of Exclusive Sample Report at: Https://Bit.Ly/2Uz40Jg

Biosimilars Market Key Players:

• Sandoz
• Pfizer
• Teva Pahrmaceutical
• Biocon
• Amgen
• Samsung Biologics
• Mylan
• Dr. Reddy’s Laboratories
• Stada Arzneimittel AG
• Genentech (Roche Group)
• Merck Serono (Merck Group)
• Celltrion Healthcare and
• AbbVie Inc.

Biosimilars Drug Clinical Trail Status of Key Companies:

Amgen:-

Biotechnology by Amgen is the story of what it takes to deliver biotechnology medicines to patients. It’s a program dedicated to raising awareness about the incredible complexity of biotechnology manufacturing. Amgen has a strong commitment to quality and reliability, has made significant, long-term investments in biologics manufacturing, and has a broad and deep knowledge of biotechnology that comes with having developed and manufactured a diverse portfolio of biotechnology medicines.

Biosimilars Market Outlook:

The global biosimilars market is driven by key factors such as rising incidence of chronic diseases, the emergence of off-patent biologic products and innovative strategies in enhanced productivity and clinical trial activities for biosimilars. Furthermore, these drugs are very cost-effective thus making its demand to increase significantly. However, factors such as lack of regulatory guidelines, high capital required for research & development, complications in manufacturing and lengthy clinical trials which are required from the regulatory bodies for approval are hampering the biosimilars market globally.

Have any Query? Speak to Analyst @ https://bit.ly/2QNvc8g

Biosimilars Market by Technology:

• Monoclonal Antibodies Technology
• Recombinant DNA Technology
• Chromatography - Protein Sequencing, Liquid Chromatography and Gas
Chromatography
• Nuclear Magnetic Resonance Technology
• Electrophoresis - Gel Electrophoresis And Capillary Electrophoresis
• Mass Spectrometry
• Western Blotting and Bioassay.

Biosimilars Market by Product:

Based on product the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins and peptides. Further, recombinant non-glycosylated proteins is bifurcated into human growth hormone, insulin, interferon and granulocyte colony stimulating factor (G-CSF). Whereas, recombinant glycosylated proteins is sub-segmented into erythropoietin, monoclonal antibodies and follitropin. Among these, recombinant non-glycosylated proteins dominated the global market in 2018, owing to rising regulatory approvals.

Biosimilars Market by Disease:

Various disease were studied in this report which includes Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency and Infectious Diseases. The oncology segment dominated the global biosimilars market in 2018. This is due to high prevalence rate of chronic disease such as cancer, rising incidence of blood disorders across the globe, low cost of biosimilars compared to biologics.

Biosimilars Market by Type:

Based on type the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The in-house manufacturing segment accounted for the largest share in 2018. The in-house method of manufacturing is first choice of biosimilars manufacturers as they can develop biosimilars in their own laboratories, this can exclude shipping and delivery costs.

Biosimilars Market Report Buy Now at https://bit.ly/2RYuiD6

Biosimilars Market by Geography:

The biosimilars market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. The Europe dominated the biosimilars market in 2018, owing to the rising geriatric population, successive increase in the incidence of age-related disorders and chronic disorders. However, Asia-Pacific is anticipated to be the fastest-growing region for the biosimilars market.

About Us:

Axiom Market Research & Consulting™ offers market research and data analytics services such as syndicated market research reports, custom market research reports, business consulting, consumer/end user survey, data processing & analytical services, social media analytics across various industry verticals such as, Life Science, Chemicals &Materials, Food & Beverages, Packaging Agriculture, Power & Energy.

Axiom MRC with its experienced team of research and data analysts, has delivered number of market research and data analytics projects across the global. With a worldwide client base, Axiom Market Research & Consulting™ aims to be a global leader and defacto partner in your company’s growth.

Contact Us:
Manish Shelar
Telephone: +1 (845) 875-9786
Email: sales@axiommrc.com
Website: http://axiommrc.com

This release was published on openPR.